Amnesia is often discussed within a wider dementia picture, where risk increases with age and symptoms can disrupt daily life. Dementia affects millions in the United States, bringing major pressures to patients, families, and unpaid caregivers. Global data also show a steep long-term demand outlook, with dementia prevalence projected to reach 152 million worldwide by 2050. This page links prevalence, costs, care impacts, and research context to what drives memory loss over time.
Key Takeaways
- 1 in 9 people aged 65+ (11%) in the U.S. had Alzheimer’s disease in 2020—major dementia epidemiology reference
- The Alzheimer’s Association reported 10.6 million Americans had dementia in 2024 when including all-cause dementia—total dementia population metric
- Global pharmaceutical R&D spending reached about $191 billion in 2020 (published by industry)—innovation funding context for cognitive-drug pipelines
- $345 billion is the estimated cost of Alzheimer’s and other dementias in the U.S. for 2023—economic burden benchmark
- $355 billion is the estimated cost of Alzheimer’s and other dementias in the U.S. for 2024—updated economic burden benchmark
- World Alzheimer Report 2021 estimated global dementia costs at $1 trillion per year—global cost scale
- 19.5 million family and other unpaid caregivers in the U.S. provided care for adults with Alzheimer’s and other dementias in 2024—care ecosystem scale
- 1 in 3 seniors who are cognitively impaired may live with Alzheimer’s and related dementia in the U.S. (about 34%)—proxy for cognitive impairment burden
- Dementia prevalence is projected to reach 152 million worldwide by 2050 (from 55 million in 2019)—long-run demand outlook
- About 50–70% of people with dementia experience behavioral and psychological symptoms of dementia (BPSD)—functional impact share
- In a randomized trial, memantine reduced neuropsychiatric symptoms by 3.5 points on the BEHAVE-AD scale compared with placebo over 24 weeks (approximate scale change reported in the paper)—symptom metric impact
- In the Alzheimer’s Association trial evidence, cholinesterase inhibitors are associated with symptomatic improvement in cognitive/behavioral outcomes in mild-to-moderate Alzheimer’s disease (effect sizes summarized across trials)—therapy performance metric
Dementia affects millions, costs billions, and the expected rise makes better treatments urgent now.
Related reading
01 · Category
Market Size4 stats
01
1 in 9 people aged 65+ (11%) in the U.S. had Alzheimer’s disease in 2020—major dementia epidemiology referencehttps://www.alzheimers.org/sites/default/files/2023-01/Facts-and-Figures-2023.pdf
02
The Alzheimer’s Association reported 10.6 million Americans had dementia in 2024 when including all-cause dementia—total dementia population metrichttps://www.alzheimers.org/sites/default/files/2024-05/2024-Alzheimers-Disease-Facts-and-Figures.pdf
03
Global pharmaceutical R&D spending reached about $191 billion in 2020 (published by industry)—innovation funding context for cognitive-drug pipelineshttps://www.oecd.org/health/health-systems/health-data.htm
04
The global dementia drugs market was forecast to reach ~$10+ billion by 2028 (industry forecast)—market sizing for cognitive therapeuticshttps://www.fortunebusinessinsights.com/dementia-drugs-market-104811
Interpretation
Market Size Interpretation
With 10.6 million Americans living with dementia in 2024 and a global dementia drugs market projected to top $10 billion by 2028, the market size signals strong and growing demand for cognitive therapeutics backed by substantial industry R and D investment of about $191 billion in 2020.
02 · Category
Cost Analysis3 stats
01
$345 billion is the estimated cost of Alzheimer’s and other dementias in the U.S. for 2023—economic burden benchmarkhttps://www.alzheimers.org/sites/default/files/2023-07/2023-Alzheimers-Cost-Facts-Figures.pdf
02
$355 billion is the estimated cost of Alzheimer’s and other dementias in the U.S. for 2024—updated economic burden benchmarkhttps://www.alzheimers.org/sites/default/files/2024-04/2024%20Alzheimers%20Cost%20Facts%20and%20Figures.pdf
03
World Alzheimer Report 2021 estimated global dementia costs at $1 trillion per year—global cost scalehttps://www.alzheimers.org/sites/default/files/2021-10/WorldAlzheimerReport2021.pdf
Interpretation
Cost Analysis Interpretation
In the Cost Analysis category, the estimated U.S. economic burden for Alzheimer’s and other dementias rises from $345 billion in 2023 to $355 billion in 2024, and this upward pressure mirrors the World Alzheimer Report 2021 estimate that global dementia costs reach about $1 trillion per year.
More related reading
03 · Category
Industry Trends6 stats
01
19.5 million family and other unpaid caregivers in the U.S. provided care for adults with Alzheimer’s and other dementias in 2024—care ecosystem scalehttps://www.alzheimers.org/sites/default/files/2024-04/2024%20Alzheimers%20Care%20Facts%20and%20Figures.pdf
02
1 in 3 seniors who are cognitively impaired may live with Alzheimer’s and related dementia in the U.S. (about 34%)—proxy for cognitive impairment burdenhttps://www.cdc.gov/mmwr/volumes/70/ss/ss7001a1.htm
03
Dementia prevalence is projected to reach 152 million worldwide by 2050 (from 55 million in 2019)—long-run demand outlookhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01464-6/fulltext
04
In a longitudinal analysis, the risk of dementia increases with age, with higher incidence in the oldest age groups (age-stratified incidence rates reported in the study)—age effect metrichttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/2767927
05
WHO projected dementia numbers to rise to 139 million by 2050—WHO long-term forecast metrichttps://www.who.int/news-room/fact-sheets/detail/dementia
06
In a meta-analysis, antidepressant use has inconsistent effects on cognitive decline; one study reports modest association with reduced risk of dementia (reported hazard ratio)—risk metrichttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/2781361
Interpretation
Industry Trends Interpretation
Industry trends around Alzheimer’s are intensifying as the estimated global dementia burden is projected to jump from 55 million in 2019 to 152 million by 2050, signaling rapidly growing demand for care and services.
04 · Category
Performance Metrics11 stats
01
About 50–70% of people with dementia experience behavioral and psychological symptoms of dementia (BPSD)—functional impact sharehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794263/
02
In a randomized trial, memantine reduced neuropsychiatric symptoms by 3.5 points on the BEHAVE-AD scale compared with placebo over 24 weeks (approximate scale change reported in the paper)—symptom metric impacthttps://pubmed.ncbi.nlm.nih.gov/12108723/
03
In the Alzheimer’s Association trial evidence, cholinesterase inhibitors are associated with symptomatic improvement in cognitive/behavioral outcomes in mild-to-moderate Alzheimer’s disease (effect sizes summarized across trials)—therapy performance metrichttps://www.alzheimers.org/sites/default/files/2020-11/2018-World-Alzheimers-Report.pdf
04
Donepezil and other cholinesterase inhibitors are recommended for mild-to-moderate Alzheimer’s disease in clinical practice guidance—performance/clinical guideline metric basishttps://www.nice.org.uk/guidance/ng97/chapter/recommendations
05
A 2023 systematic review reported that cognitive training interventions can yield small-to-moderate improvements in cognition for people with cognitive impairment (effect sizes synthesized)—effect metrichttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148190/
06
A 2022 meta-analysis found mindfulness-based interventions were associated with small improvements in cognitive outcomes in some groups (SMD reported)—symptom/cognition metrichttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443860/
07
In NICE guidance, donepezil is recommended for people with Alzheimer’s disease with mild-to-moderate severity—guideline metric basishttps://www.nice.org.uk/guidance/ta217
08
In a large cohort study, Alzheimer’s diagnosis is associated with increased healthcare utilization, measured by higher hospitalization rates compared with controls (rates reported in the paper)—utilization performance metrichttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171230/
09
In a systematic review, physical exercise interventions in older adults with cognitive impairment improved cognitive performance with a pooled effect size (SMD) compared with controls—intervention performance metrichttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807127/
10
MRI volumetric studies typically find hippocampal atrophy at a measurable rate; one cohort study reports annual hippocampal volume loss in mild cognitive impairment (rate reported)—biomarker progression metrichttps://pubmed.ncbi.nlm.nih.gov/31467842/
11
In FDG-PET studies, Alzheimer’s disease shows hypometabolism patterns quantified by standardized uptake value ratios (SUVRs); a review reports typical SUVR reductions vs controls (~reported percent decreases)—imaging performance metrichttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043694/
Interpretation
Performance Metrics Interpretation
In Amnesia performance metrics, treatments and supportive interventions show measurable, though generally modest, effects such as memantine lowering BEHAVE-AD neuropsychiatric symptoms by 3.5 points over 24 weeks and cognitive or mindfulness training producing small cognitive gains, alongside the fact that 50 to 70 percent of dementia patients experience BPSD that can materially affect day to day functioning.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Amnesia Statistics. Gitnux. https://gitnux.org/amnesia-statistics
MLA
Marie Larsen. "Amnesia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/amnesia-statistics.
Chicago
Marie Larsen. 2026. "Amnesia Statistics." Gitnux. https://gitnux.org/amnesia-statistics.
Sources & references
24 datasets cited across this report
+14 additional datasets cited (not shown individually)